JP2022537349A - 療法に使用するためのｐａｒｐ１４の標的タンパク質分解 - Google Patents

療法に使用するためのｐａｒｐ１４の標的タンパク質分解 Download PDF

Info

Publication number
JP2022537349A
JP2022537349A JP2021575326A JP2021575326A JP2022537349A JP 2022537349 A JP2022537349 A JP 2022537349A JP 2021575326 A JP2021575326 A JP 2021575326A JP 2021575326 A JP2021575326 A JP 2021575326A JP 2022537349 A JP2022537349 A JP 2022537349A
Authority
JP
Japan
Prior art keywords
alkyl
methyl
pharmaceutically acceptable
compound
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021575326A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022537349A5 (enExample
Inventor
ビー シェンケル，ローリー
メアリー バズビンダー，メリッサ
ウェイン カンツ，ケビン
カライ スウィンガー，カレン
ジェイ エヌ ウィグル，ティモシー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ribon Therapeutics Inc
Original Assignee
Ribon Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ribon Therapeutics Inc filed Critical Ribon Therapeutics Inc
Publication of JP2022537349A publication Critical patent/JP2022537349A/ja
Publication of JP2022537349A5 publication Critical patent/JP2022537349A5/ja
Priority to JP2025061199A priority Critical patent/JP7844707B2/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/021—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)n-C(=0)-, n being 5 or 6; for n > 6, classification in C07K5/06 - C07K5/10, according to the moiety having normal peptide bonds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2021575326A 2019-06-19 2020-06-18 療法に使用するためのｐａｒｐ１４の標的タンパク質分解 Pending JP2022537349A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025061199A JP7844707B2 (ja) 2019-06-19 2025-04-02 療法に使用するためのｐａｒｐ１４の標的タンパク質分解

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962863357P 2019-06-19 2019-06-19
US62/863,357 2019-06-19
PCT/US2020/038377 WO2020257416A1 (en) 2019-06-19 2020-06-18 Targeted protein degradation of parp14 for use in therapy

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025061199A Division JP7844707B2 (ja) 2019-06-19 2025-04-02 療法に使用するためのｐａｒｐ１４の標的タンパク質分解

Publications (2)

Publication Number Publication Date
JP2022537349A true JP2022537349A (ja) 2022-08-25
JP2022537349A5 JP2022537349A5 (enExample) 2023-06-27

Family

ID=71527971

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021575326A Pending JP2022537349A (ja) 2019-06-19 2020-06-18 療法に使用するためのｐａｒｐ１４の標的タンパク質分解
JP2025061199A Active JP7844707B2 (ja) 2019-06-19 2025-04-02 療法に使用するためのｐａｒｐ１４の標的タンパク質分解

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025061199A Active JP7844707B2 (ja) 2019-06-19 2025-04-02 療法に使用するためのｐａｒｐ１４の標的タンパク質分解

Country Status (11)

Country Link
US (2) US20220388985A1 (enExample)
EP (1) EP3986887A1 (enExample)
JP (2) JP2022537349A (enExample)
KR (1) KR20220024098A (enExample)
CN (2) CN114206853A (enExample)
AU (1) AU2020296063B2 (enExample)
BR (1) BR112021025645A2 (enExample)
CA (1) CA3142002A1 (enExample)
MA (1) MA56513A (enExample)
SG (1) SG11202112980TA (enExample)
WO (1) WO2020257416A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2941818T3 (es) * 2017-12-21 2023-05-25 Ribon Therapeutics Inc Quinazolinonas como inhibidores de PARP14
WO2022150667A1 (en) * 2021-01-08 2022-07-14 The Board Of Regents Of The University Of Texas System Nimbolide analogs and methods of use thereof
TW202241426A (zh) * 2021-01-29 2022-11-01 美商律幫治療股份有限公司 治療發炎疾病之方法
CN114890989B (zh) * 2022-05-25 2024-03-22 广东晨康生物科技有限公司 一种含氮衍生物为Linker的HDAC8降解剂其制备方法和应用
CN117229224B (zh) * 2022-06-07 2026-05-08 中国药科大学 喹唑啉-4(3h)-酮类化合物、制法、组合物和应用
MA71624A (fr) 2022-07-29 2025-05-30 Abbvie Operations Singapore Pte. Ltd. Dégradation de protéine ciblée de parp14 pour une utilisation en thérapie
KR20250055508A (ko) 2022-07-29 2025-04-24 애브비 오퍼레이션즈 싱가포르 피티이. 리미티드 치료에 사용하기 위한 parp14의 표적 단백질 분해
CN117658983A (zh) * 2022-09-01 2024-03-08 浙江文达医药科技有限公司 选择性parp1抑制剂
WO2024251205A1 (zh) * 2023-06-06 2024-12-12 西藏海思科制药有限公司 一种喹唑啉酮衍生物及其在医药上的应用
CN116813640A (zh) * 2023-06-29 2023-09-29 成都金瑞基业生物科技有限公司 一类抑制并降解parp的化合物及应用

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014036022A1 (en) * 2012-08-29 2014-03-06 Amgen Inc. Quinazolinone compounds and derivatives thereof
JP2015508414A (ja) * 2012-01-12 2015-03-19 イエール ユニバーシティ Ｅ３ユビキチンリガーゼによる標的タンパク質および他のポリペプチドの分解増強のための化合物および方法
WO2018102067A2 (en) * 2016-11-01 2018-06-07 Arvinas, Inc. Tau-protein targeting protacs and associated methods of use
WO2018148440A1 (en) * 2017-02-08 2018-08-16 Dana-Farber Cancer Institute, Inc. Regulating chimeric antigen receptors
WO2019014429A1 (en) * 2017-07-12 2019-01-17 Dana-Farber Cancer Institute, Inc. COMPOUNDS FOR THE DEGRADATION OF TAU PROTEIN

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY180775A (en) * 2014-04-23 2020-12-09 Incyte Corp 1h-pyrrolo[2,3-c]pyridin-7(6h)-ones and pyrazolo[3,4-c]pyridin-7(6h)-ones as inhibitors of bet proteins
WO2017197056A1 (en) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. Bromodomain targeting degronimers for target protein degradation
ES2941818T3 (es) * 2017-12-21 2023-05-25 Ribon Therapeutics Inc Quinazolinonas como inhibidores de PARP14

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015508414A (ja) * 2012-01-12 2015-03-19 イエール ユニバーシティ Ｅ３ユビキチンリガーゼによる標的タンパク質および他のポリペプチドの分解増強のための化合物および方法
WO2014036022A1 (en) * 2012-08-29 2014-03-06 Amgen Inc. Quinazolinone compounds and derivatives thereof
WO2018102067A2 (en) * 2016-11-01 2018-06-07 Arvinas, Inc. Tau-protein targeting protacs and associated methods of use
WO2018148440A1 (en) * 2017-02-08 2018-08-16 Dana-Farber Cancer Institute, Inc. Regulating chimeric antigen receptors
WO2019014429A1 (en) * 2017-07-12 2019-01-17 Dana-Farber Cancer Institute, Inc. COMPOUNDS FOR THE DEGRADATION OF TAU PROTEIN

Also Published As

Publication number Publication date
JP7844707B2 (ja) 2026-04-13
MA56513A (fr) 2022-04-27
US20260125362A1 (en) 2026-05-07
EP3986887A1 (en) 2022-04-27
WO2020257416A1 (en) 2020-12-24
AU2020296063A1 (en) 2021-12-23
BR112021025645A2 (pt) 2022-02-01
AU2020296063B2 (en) 2026-01-29
KR20220024098A (ko) 2022-03-03
SG11202112980TA (en) 2021-12-30
CN114206853A (zh) 2022-03-18
CA3142002A1 (en) 2020-12-24
CN120398840A (zh) 2025-08-01
US20220388985A1 (en) 2022-12-08
JP2025102917A (ja) 2025-07-08

Similar Documents

Publication Publication Date Title
JP7844707B2 (ja) 療法に使用するためのｐａｒｐ１４の標的タンパク質分解
US11958837B2 (en) Quinazolinones as PARP14 inhibitors
JP7721501B2 (ja) Ｃｄ３８の阻害剤としてのヘテロ二環式アミド
JP2025160175A (ja) Ｃｄ３８阻害剤としてのキノリン及びアザキノリン
JP2014231475A (ja) 新規化合物及びそのｐｄｅ１０阻害薬としての使用
JP2015506936A (ja) ピペラジニルピリミジン誘導体、その製造方法及び使用
TW202417434A (zh) 用於治療之parp14之靶向蛋白質降解
HK40039341B (en) Quinazolinones as parp14 inhibitors
HK40039341A (en) Quinazolinones as parp14 inhibitors

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230616

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230616

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20240423

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240507

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240718

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20241203